Core Viewpoint - The company reported a significant decline in revenue and net profit for the fiscal year 2025, primarily due to industry policy impacts and increased competition in the in vitro diagnostics sector [1] Financial Performance - The company achieved an operating revenue of 407.69 million yuan, a decrease of 20.20% compared to the same period last year [1] - The net profit attributable to the parent company was -210.52 million yuan, with a net profit excluding non-recurring gains and losses of -258.11 million yuan [1] Industry Impact - The in vitro diagnostics industry faced challenges from centralized procurement policies, leading to a short-term decline in domestic prices and reduced demand, contributing to a revenue drop of 103.21 million yuan [1] - Changes in national tax policies for the industry also negatively affected revenue [1] Asset Impairment - The company recognized an impairment loss of 38.01 million yuan on related operating assets, including reagents and equipment, following its consistent impairment policy [1] Investments and R&D - The company increased its investment in the joint venture ShunJing Pharmaceutical, which became a subsidiary and was included in the consolidated financial statements [1] - ShunJing Pharmaceutical continued to advance its innovative drug pipeline, with R&D expenditures amounting to 78.62 million yuan during the reporting period [1] - The company also reported investment losses of 13.51 million yuan from joint ventures such as YaoJing Gene and ZhiYuan Bio, which increased their R&D investments in the field of biopharmaceuticals [1]